Merger with AlloVir - Schedule of Number of Shares Common Stock Issued and Outstanding (Details) - Common Stock - AlloVir |
Mar. 18, 2025
shares
|
|---|---|
| Business Combination, Consideration Transferred, Equity Interest [Line Items] | |
| AlloVir's common stock outstanding | 5,043,652 |
| AlloVir's restricted stock units accelerated and settled in common stock | 24,022 |
| Common stock issued to Legacy Kalaris' securityholders at the Effective Time | 13,634,744 |
| Total | 18,702,418 |
| X | ||||||||||
- Definition Business acquisition equity interest restricted stock units accelerated and settled. No definition available.
|
| X | ||||||||||
- Definition Business acquisition equity interests number of shares issued and outstanding. No definition available.
|
| X | ||||||||||
- Definition Business acquisition equity interests outstanding. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of shares of equity interest issued or issuable by acquirer as part of consideration transferred in business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|